Search Orphan Drug Designations and Approvals
-
Generic Name: | Sitaxsentan Sodium |
---|---|
Date Designated: | 11/02/2004 |
Orphan Designation: | For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure. |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Pfizer Global Research and Development 50 Pequot Avenue 6025-B4137 New London, Connecticut 06320 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-